Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

FEI announces final decision in banned substance case
Horse racing
During the FEI tribunal, Dr Kamaal admitted that he had administered Fustex, a product that contains Propxyphene.
Staff member administered product containing Propoxyphene

A two-year suspension has been imposed on Dr Pasha Syed Kamaal after a banned substance was detected at a UAE event, the FEI has confirmed.

Dr Kamaal was identified as a member of support staff in a 2012 equine anti-doping case which involved a horse ridden by HH Sheik Hazza.

Samples taken from the horse returned positive for the banned substance Propoxyphene, an opioid analgesic, and its metabolite Norpropoxyphene.

In addition to a two-year suspension, Dr Kamaal has also received a fine of CHF 2,500 and costs of CHF 1,000.

Previously, the FEI imposed a 27-month suspension on HH Sheikh Hazza as the person responsible, but this was reduced to 18 months following an appeal to the Court of Arbitration for Sport.

During the FEI tribunal, Dr Kamaal admitted that he had administered Fustex, an Argentinian product, to the horse the night before the event.

Used to promote muscle growth, Fustex contains Propoxyphene but it is not yet listed as an ingredient.

The FEI has since issued a statement to stakeholders urging caution over the use of Fustex. They warn that lack of knowledge is no valid excuse in any anti-doping procedures. 

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'